Prevalence of Thyroid Cancer at a Medical Screening Center: Pathological Features of Screen-detected Thyroid Carcinomas

Yoon Jung Choi,1 Yong Lai Park,2 and Jang Hyun Koh3

Departments of 1Radiology and 2Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul; 3Health Promotion Center, Samsung Seoul Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

INTRODUCTION

The widespread use of high resolution sonography (HRS)1 as a screening tool for thyroid cancer in medical health care in Korea is increasing,2 and its use has generated a number of issues. There is very limited evidence of the use of the modality to be cost effective.3 Furthermore, the management of thyroid nodules detected during screening with HRS remains controversial. Performing screening HRS for thyroid cancer can lead to the identification of a large number of small benign-appearing nodules and can lead to unnecessary studies thus increasing the cost of health care.4 However, the demand for screening HRS by the self-referred patient is on the increase, and the medical faculty does not currently intervene in the decision of patients to undergo screening. The rate of thyroid cancer for screen-detected thyroid nodules at medical centers in Korea is increasing due to better performance of fine-needle aspiration biopsy (FNAB) and ultrasound (US).5-8 The incidence of thyroid cancer for screening thyroid US has been reported in limited studies,9 and previous reports were mainly based on the finding of autopsy cases with a wide range of malignancy rates of 5-35%.10-12 We investigated the actual prevalence of thyroid cancer in a voluntary cancer-screening program in healthy subjects without a previous history of malignancy to evaluate the value of ultrasound for screening thyroid cancer.

As previously reported, many autopsy studies have suggested that most occult thyroid carcinomas follow a relatively benign or indolent course,12,13 and there has been a recognition of
different biological behavior between the really "occult" and clinically overt cancers. We, therefore, compared the clinical and pathological features of screen-detected thyroid cancers to symptomatic cancers to evaluate if a different approach of management is necessary.

MATERIALS AND METHODS

Patient selection

From March 2006 to February 2008, 7,491 consecutive subjects underwent screening thyroid HRS at a medical health care center, Kangbuk Samsung Hospital, in the Republic of Korea. Informed consent was waived for all patients who underwent thyroid US and FNAB. Approximately 37% of patients (n = 2,747) had a thyroid nodule or nodules. Among these subjects, 658 patients (24%) underwent fine needle aspiration for having a solid nodule larger than 1 cm or a nodule less than 1 cm, however, showed at least one malignant US feature. Seventy-nine patients (12%) had a cytology result of being positive for a malignancy and 46 patients underwent a surgical procedure at our hospital (Fig. 1).

During the same period, 287 referred patients underwent the FNAB procedure at the Department of Radiology, and 254 patients underwent a surgical procedure. Patients (n = 157) who had at least 1 of the following symptoms or had overlapping symptoms, including a palpable neck lesion (n = 89), voice change (n = 21), swallowing difficulty (n = 6) and neck pain (n = 54), were included as representing patients with symptomatic thyroid cancer. When there was more than one cancer nodule confirmed, the largest major lesion was considered for evaluation, whereas ipsilateral smaller lesions were disregarded for the pathological analysis. For statistical purposes of comparison, bilateral symptomatic thyroid cancer (n = 2) cases were excluded from the study.

![Fig. 1. Flow chart of patients undergoing high resolution ultrasound at a medical center for thyroid cancer screening. US, ultrasound; F/U, follow up.](image-url)
US imaging

We used an HDI 5000 (Advanced Technology Laboratories, Bothell, WA, USA), IU22 (Philips Medical Systems, Bothell, WA, USA), or LOGIQ 700 ultrasound scanner (GE Medical Systems, Milwaukee, WI, USA) equipped with a 5-12 MHz linear-array transducer. Board-certified radiologists with at least 5 years of experience in thyroid US performed all of the sonographic examinations.

Indications for US guided FNAB for nodules that were larger than 1 cm were based primarily on the internal content of the lesions. A predominantly cystic nodule (cyst portion more than 50%) and nodules with an internal spongiform appearance were not candidates for FNAB. Candidates for FNAB for nodules less than 1 cm on the longest diameter on a longitudinal scan were nodules with at least 1 finding of microcalcifications, an irregular shape, an ill defined margin and a solid nodule with echogenicity that was lower than the echogenicity of strap muscle.

Three board certified radiologists performed US-FNAB using a 23-gauge needle attached to a 10 cc syringe with an aspirator. Movement of the needle tip toward and into the target was visualized by real time-US. Based on a cytological evaluation, nodules were classified as malignant, indeterminant, benign, or an inadequate sample. A positive malignant cell based on an FNAB cytology finding was considered as a screen-detected thyroid cancer.

We compared 46 screen-detected thyroid cancers to 157 symptomatic thyroid cancers to determine if there were any existing differences in age, gender, size of the cancer, peri-thyroidal extension, lympho-vascular invasion, underlying pathology, stage, and lymph node invasion status and pathological type. The underlying pathologies were evaluated and compared to clinically overt tumors. We also compared the above-mentioned features of micropapillary carcinomas (MPCs) (n = 111) to papillary thyroid carcinomas (PTCs) (n = 92) to evaluate different findings.

Statistical analysis was performed by use of chi-squared test or Fisher’s exact test to compare categorical variables, and by Student’s t-test to compare continuous variables between groups using SPSS version 10.0 (Chicago, IL, USA). Probability levels less than 0.05 were considered as statistically significant.

RESULTS

Thyroid HRS performed as screening for thyroid cancer

For two consecutive years, 7,491 subjects underwent screening of thyroid HRS. Among the subjects screened, 2,477 (33%) participants had a normal thyroid and 1,626 participants (21.7%) presented with a colloid cyst. Approximately 76 subjects (1%) had lesions that were suspicious for diffuse thyroid infiltrative disease with heterogenous coarse mixed parenchymal echogenicity with nodular enlargement, and 547 subjects (6.9%) were diagnosed with a US feature that was suspicious of thyroiditis. There were 2,747 subjects (36.7%) with thyroid nodules. Fig. 1 demonstrates the flow chart of nodule evaluation. Among subjects that had a thyroid nodule or nodules (n = 2,747), 658 patients (23.95%) underwent FNAB for presenting with a solid nodule larger than 1 cm or a nodule less than 1 cm, however, showed at least one US feature suggestive of a malignancy. Table 1 shows the cytology results of FNAB for the screened patients, symptomatic patients and nodules according to sizes. Of the subjects screened, 461 subjects (70.0%) were negative for a malignancy, based on a cytology finding, 79 subjects (12.0%) were positive for a malignancy, 22 (3.3%) subjects had an indeterminate cytology, and 96 subjects (14.6%) had an inadequate cellular sample for diagnosis. In symptomatic referred patients, malignant cell cytology was identified in 59.2% of patients. When categorized according to size, 24.9% of inadequate specimens consisted of a nodule less than 1 cm in size and only 1.5% of inadequate specimens consisted of nodules larger than 1 cm. Table 2 depicts the cytology results of 46 patients whose nodules were identified by screening US at the medical screening center. Having an underlying pathology did not influence the preoperative diagnostic rate by FNAB for screen-identified cancers and clinical overt thyroid cancers (p = 0.811).
Table 1. Fine-needle Aspiration Results in Screen-identified Nodules and Clinically Overt Nodules

| FNAB cytology result | Nodules identified by screening US (n = 658) | Clinical overt thyroid nodules (n = 287) | Nodules less than 1 cm (n = 189) | Nodules larger than 1 cm (n = 756) |
|----------------------|---------------------------------------------|----------------------------------------|----------------------------------|-----------------------------------|
| Benign, n (%)        | 461 (70.0%)                                 | 56 (19.5%)                             | 24 (12.7%)                       | 553 (73.1%)                       |
| Malignant, n (%)     | 79 (12.0%)                                  | 170 (59.2%)                            | 93 (49.2%)                       | 88 (11.6%)                       |
| Indeterminate, n (%) | 22 (3.3%)                                   | 30 (10.5%)                             | 25 (13.2%)                       | 104 (13.8%)                      |
| Inadequate, n (%)    | 96 (14.6%)                                  | 31 (10.8%)                             | 47 (24.9%)                       | 11 (1.5%)                        |

FNAB, fine-needle aspiration biopsy; US, ultrasound.

Table 2. Surgically Confirmed Thyroid Malignant Nodules on Screening Ultrasound at a Medical Screening Center

| US impression       | Fine-needle aspiration cytology result | Pathology                     |
|---------------------|---------------------------------------|-------------------------------|
|                      | Benign  | Indeterminate | Malignant | Follicular carcinoma | Hurthle cell carcinoma | Papillary carcinoma |
| Benign (n = 3)      | 0       | 0             | 3         | 0                   | 0                    | 0                   |
| Borderline (n = 8)  | 1       | 2             | 5         | 1                   | 2                    | 0                   |
| Malignant (n = 35)  | 1       | 3             | 31        | 0                   | 0                    | 43                  |
| Total (n = 46)      | 2       | 5             | 39        | 1                   | 2                    | 43                  |

US, ultrasound.

Comparison of clinically overt and occult PMCs

Table 3 summarizes and compares the clinico-pathological features of patients with screen-detected cancers and symptomatic thyroid cancers. The size of symptomatic cancers was significantly larger than the screen-detected tumors (1.141 ± 0.796 cm versus 0.852 ± 0.439 cm; p = 0.002) and was statistically significant. Out of 46 (65%) surgically confirmed screen-identified cancers, 30 cancers were identified as microcarcinomas. Thyroid cancers were found more frequently in women in screened subjects as well as symptomatic subjects (p = 0.339), and age was not a statistically significant factor. Differences in extrathyroidal extension (34.8% vs. 40.8%), vascular invasion (8.7% vs. 4.5%), and cervical lymph node invasion (28.3% versus 29.9%) were not statistically significant between the screened subjects and symptomatic subjects (p < 0.005). Of 46 patients with occult tumors, 19 patients (41.3%) were in stage 3, and they underwent a bilateral thyroidectomy and central neck node dissection with lateral lymph node dissection, whereas 59 of 157 patients (37.6%) with clinically overt PTCs were diagnosed as stage 3 and received a bilateral thyroidectomy (p = 0.808). The histological type was mainly well-differentiated type papillary carcinomas in both screened subjects as well as in the symptomatic subjects. For screen-identified cancers, 93.5% of the cancers were papillary, 2 cancers were Hurthle cell carcinomas and 1 patient was diagnosed with a follicular carcinoma. For the symptomatic patients, 97.5% were identified with papillary cancers and 4 patients had a follicular carcinoma.

Comparison of PMCs and PTCs

When PMCs and PTCs were compared and analyzed (Table 4), extrathyroidal extension (25.2% versus 56.5%), vascular invasion (0.9% versus 7.6%), lymphatic invasion (1.8% vs. 9.8%) and cervical lymph node invasion (20.7% vs. 40.2%) occurred more frequently in papillary carcinomas larger than 1 cm in the longest diameter and with a higher stage (stage 3, 31.5% vs. 46.7%). These findings were statistically significant (p < 0.005).
DISCUSSION

Rate of malignancy in thyroid nodules detected at a medical screening center

Thyroid nodules are found by palpation in 4 - 8% of the general population in adults, and are more frequently detected at a rate of 30 - 50% on sonography and 50% in autopsy cases. The malignancy rate has been reported at 7 - 15%, and the malignancy rate within thyroid incidentalomas was 12 - 28.8%. The malignancy rate is increasing due to wide use of highly sensitive US for routine health examinations. The rate of thyroid incidentalomas at our institute was 36.67%, with a malignancy rate of 12%. The malignancy rates for thyroid incidentaloma, however, differ among institutes, and this difference may be due to a selection bias of candidates selected for FNAB that is different among various institutes. In our institution, solid nodules larger than 1 cm are considered as candidates for FNAB. Nodules less than 1 cm in the longest diameter with at least 1 US feature of suspicious malignant finding are also considered as candidates for FNAB. When nodules are depicted as purely cystic nodules, nodules are not considered as candidates for FNAB, regardless of size. There are US characteristics of thyroid malignancies that distinguish nodules from benign nodules to suspicious of malignancy nodules, but some of the features overlap. Further studies are needed to obtain a consensus of FNAB indications for screen-detected

Table 3. Patients and Pathological Features of Thyroid Cancer

| Characteristics                        | Screening C (n = 46) | Symptomatic Ca (n = 157) | p value |
|----------------------------------------|---------------------|--------------------------|---------|
| Patient characteristics                |                     |                          |         |
| Age (yrs)                              | 51.13 ± 11.56       | 48.15 ± 11.24            | 0.118   |
| Sex                                    |                     |                          |         |
| Female                                 | 39/46 (84.8%)       | 123/157 (78.3%)          | 0.339   |
| Male                                   | 7/46 (15.2%)        | 25/157 (21.7%)           |         |
| Pathological finding                   |                     |                          |         |
| Size                                   | 0.599 ± 0.154       | 1.650 ± 0.758            | 0.000   |
| Rate of micro PTC                      | 29 (63%)            | 54 (34.4%)               | 0.000   |
| Capsule invasion                       | 16/46 (34.8%)       | 64/157 (40.8%)           | 0.465   |
| Lymphatic invasion                     | 4/46 (8.7%)         | 7/157 (4.5%)             | 0.274   |
| Blood vessel invasion                  | 1/46 (2.2%)         | 7/157 (4.5%)             | 0.686   |
| Underlying pathology                   | 14/46 (33.3%)       | 46/157 (29.3%)           | 0.561   |
| Stage                                  |                     |                          |         |
| 1. 27/46 (58.7%)                       |                     | 1. 95/157 (60.5%)        | 0.808   |
| 2. 0 (0%)                              |                     | 2. 3/157 (1.9%)          |         |
| 3. 19/46 (41.3%)                       |                     | 3. 59/157 (37.6%)        |         |
| Histology type                         | Papillary 43/46 (93.5%) | Papillary 153/157 (97.5%) | 0.811   |
|                                        | Hurthle cell 2 (4.3%) | Follicular 4/157 (2.5%)  |         |
|                                        | Follicular 1/46 (2.2%) |                          |         |
| LN invasion                            | 13/46 (28.3%)       | 47/157 (29.9%)           | 0.827   |

LN, lymph nodes; PTC, papillary thyroid carcinoma; C, indicates screen detected cancer; Ca, cancer.
nodules and US features of benign nodules with high diagnostic accuracy to preclude the undertaking of an FNAB. The rate of malignancy based on the cytology results is higher in nodules less than 1 cm (49.2% vs. 11.6%) because of the FNAB indications employed.

Wide use of screening thyroid US at medical centers in Korea to detect thyroid cancer is difficult because of limited evidence of cost effectiveness along with controversies remaining in management of the disease. However, screening with FNAB detects early cancers that present with a smaller size, and patients can undergo treatment at an earlier stage to reduce possible morbidity and mortality. In addition, screen-detected cancers do not behave like "occult" or indolent cancers, but the pathological characteristics are more similar to the characteristics of symptomatic clinical overt cancers, indicating that there are benefits of screening thyroid US. When a self-referred patient demands screening HRS, there is no reason to counter the demand or decision to undertake HRS, because of high malignancy rate observed with screen-detected thyroid nodules and early detection of smaller sized cancers.

**Differences between screen-detected cancers and symptomatic thyroid cancers**

The gender distribution of thyroid cancers was not different between subjects with screen-detected and clinically overt thyroid cancers. More females than males presented with cancers, as has been reported previously. Age is an important prognostic factor relative to mortality in thyroid cancer. In our study, however no statistical age differences existed between screen-detected thyroid cancers and clinically overt cancers. Age as a risk factor should be evaluated with a prospective study of thyroid cancer prognosis, but

---

Table 4. Patient and Pathological Features of Papillary Microcarcinomas (Longest Diameter <1 cm) and Papillary Thyroid Carcinomas (>1 cm)

| Characteristics | Microcarcinoma (PMC) (n = 111) | Papillary thyroid carcinoma (PTC >1 cm) (n = 157) | p value |
|-----------------|-------------------------------|---------------------------------|--------|
| Patient characteristics |
| Age (yrs) | 48.46 ± 10.49 | 49.27 ± 12.36 | 0.613 |
| Sex |
| Female | 88/111 (79.3%) | 74/92 (80.4%) | 0.838 |
| Male | 23/111 (20.7%) | 18/92 (19.6%) |
| Pathological finding |
| Size | 0.599 ± 0.1540 | 1.650 ± 0.758 | 0.000 |
| Capsule invasion | 28/111 (25.2%) | 52/92 (56.5%) | 0.000 |
| Lymphatic invasion | 2/111 (1.8%) | 9/92 (9.8%) | 0.025 |
| Blood vessel invasion | 1/111 (0.9%) | 7/92 (7.6%) | 0.024 |
| Underlying pathology | 41/111 (36.9%) | 35/92 (38.0%) | 0.871 |
| Stage |
| 1. 76/111 (75.5%) | 1. 46/92 (50.0%) |
| 2. 0 (0%) | 2. 3/92 (3.3%) | 0.016 |
| 3. 35/111 (31.5%) | 3. 43/92 (46.7%) |
| Histology type |
| Papillary 111/111(100%) | Papillary 85/92 (92.4%) |
| Hurthle cell 2 |
| Follicular 5/92 (5.5%) | | 0.006 |
| LN invasion | 23/111 (20.7%) | 37/92 (40.2%) | 0.002 |

LN, lymph nodes; PTC, papillary thyroid carcinoma; PMC, papillary microcarcinoma.
not with a cross sectional study. Most screen-detected thyroid cancers were well-differentiated thyroid cancers, and no difference in the rate was seen between screen-detected cancers and symptomatic thyroid cancers. This may be a reason for a stable mortality despite the increasing prevalence of thyroid cancer.24

Approximately 65% of surgically confirmed screen found cancers were micromalinomas, a cancer measuring less than 1 cm in the longest diameter.25 The management of micromalinomas is still controversial. An observational trial of papillary micromalinomas in 162 patient without surgical procedures by Ito et al in Japan26 showed that more than 70% of tumors either did not change or decreased in size, or enlarged by more than 10 mm in 10.2% of cases; lymph node metastasis in the lateral compartments appeared in only 1.2% of patients during follow-up. In addition, a metastasis was confirmed histologically in 50.5% of cases and multiple tumor formation was seen in 42.8% of patients with a rate of recurrence of 2.7% at 5 years and 5.0% at 8 years after surgery. Investigators suggested that papillary micromalinomas frequently did not become clinically apparent, therefore, patients can wait while tumors are not progressing, although lesions are pathologically multifocal and involve lymph nodes at an high incidence. According to our present data, performing screening thyroid US can lead to excessive and unnecessary surgical procedures. We cannot differentiate which nodule progresses aggressively and which nodule stays indolent or occult. Biological behavior of micromalinomas is currently not clear. Many published studies described an aggressive clinical course of micropapillary carcinomas, showing high lymph node invasion, therefore, there would be a very limited number of patients who would choose follow-up rather than a surgical procedure if a treatment option is given. In a study of prognostic factors and extension of thyroid micromalinomas in Korean patients, about 29.0% of patients presented with lymph node metastasis and extrathyroidal extension,27 which is concordant with our present results (Table 4). Earlier diagnosis with proper surgical removal of the tumor before distant metastasis may help improve prognosis of thyroid cancer patients. Radiological or cytological evaluation cannot determine cancer behavior, and it is standard practice in Korea to perform a thyroidectomy once a thyroid carcinoma is identified. Therefore, further prospective study on the natural history of occult thyroid carcinomas is needed.

When comparing the histopathology features in the screened-subjects and symptomatic subjects, clinically overt thyroid cancers presented with a larger size, whereas, the other clinical and pathological features were not statistically different, thus suggesting that screen found thyroid cancer and clinically overt symptomatic thyroid cancer should equally be treated. Kasai et al. reported that occult thyroid cancer follows a rather benign clinical course, suggesting a less aggressive treatment, however, also found that lymph node metastasis and extrathyroidal extension increase as the size of malignant nodules increase,28 which is concordant with our present results (Table 4). Earlier diagnosis with proper surgical removal of the tumor before distant metastasis may help improve prognosis of thyroid cancer patients. Radiological or cytological evaluation cannot determine cancer behavior, and it is standard practice in Korea to perform a thyroidectomy once a thyroid carcinoma is identified. Therefore, further prospective study on the natural history of occult thyroid carcinomas is needed. We attempted to identify any different clinical and pathological features between the screen-identified cancers and symptomatic cancers to provide evidence to justify less aggressive treatment, however, our results showed no statistical significant difference. Our findings support that screen-detected thyroid malignancies require investigation and treatment similar to those of clinically overt thyroid cancers. Since HRS detects too many small, non-palpable thyroid nodules which are mostly benign, a simple follow-up neck palpation has been suggested to be sufficient,29 however, we strongly believe that it should strictly be evaluated based on US characteristics and FNAB cytology findings once an incidentaloma is identified.

The primary limitation of this study is that the prevalence of thyroid nodules and cancer is based
on a population that requested thyroid screening ultrasound. The medical faculty did not interfere in a decision of a patient, however, this particular population of subjects may not represent a general population, because of specific age and economic status differences of patients that seek health care. Second, FNAB was not performed on every single nodule found at the medical screening center, but was performed mainly based on the presence of specific US features. No definite US feature for a benign nodule exists. Consequently the FNAB indication used can generate false negative cases, providing a selection bias. A further investigation is needed to evaluate the value of screening thyroid US and strict FNAB guidelines for screen-identified nodules. Third, this study is a retrospective study. We hypothesized that screen-identified cancers behave in a manner similar to clinically occult thyroid cancers, however, which cancer stays occult while which cancer manifests as overt disease is not known.

Although many investigators have extensively described the approach to treatment of palpable or symptomatic thyroid nodules,\textsuperscript{20,30-32} there still remains disagreement about the accepted evaluation and treatment of incidental thyroid nodules.\textsuperscript{33,34} We think that the current system of wide use of screening for thyroid cancer is difficult to justify with such limited evidence of cost effectiveness of screening and the controversies still remaining for the management of thyroid incidentalomas and microcarcinomas. However, when a self-referred patient demands screening HRS, there is no reason to interfere with the demand or decision to undergo HRS. Thus, if the medical center performs screening thyroid ultrasound, nodules found in a screening setting should strictly be managed, based on US characteristics and FNAB cytology findings, and screen-identified cancers should be treated in the same way as clinically symptomatic thyroid nodules.

REFERENCES

1. Woolner LB, Lemmon ML, Beahrs OH, Black BM, Keating FR Jr. Occult papillary carcinoma of the thyroid gland: a study of 140 cases observed in a 30-year period. J Clin Endocrinol Metab 1960;20:89-105.
2. Kim JY, Lee CH, Kim SY, Jeon WK, Kang JH, An SK, et al. Radiologic and pathologic findings of nonpalpable thyroid carcinomas detected by ultrasonography in a medical screening center. J Ultrasound Med 2008; 27:215-23.
3. Steele SR, Martin MJ, Mullenix PS, Azarow KS, Andersen CA. The significance of incidental thyroid abnormalities identified during carotid duplex ultrasonography. Arch Surg 2005;140:981-5.
4. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, et al; Society of Radiologists in Ultrasound. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2005;237: 794-800.
5. Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK. 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 2005;115: 1074-8.
6. Kang HW, No JH, Chung JH, Min YK, Lee MS, Lee MK, et al. Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid 2004; 14:29-33.
7. Lee HK, Hur MH, Ahn SM. Diagnosis of occult thyroid carcinoma by ultrasonography. Yonsei Med J 2003;44: 1040-4.
8. Nam-Goong IS, Kim HY, Gong G, Lee HK, Hong SJ, Kim WB, et al. Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) 2004;60: 21-8.
9. Brander A, Viikinkoski P, Nickels J, Kivisaari L. Thyroid gland: US screening in middle-aged women with no previous thyroid disease. Radiology 1989;173: 507-10.
10. Lang W, Borrusch H, Bauer L. Occult carcinomas of the thyroid. Evaluation of 1,020 sequential autopsies. Am J Clin Pathol 1988;90:72-6.
11. Ottino A, Pianzola HM, Castelletto RH. Occult papillary thyroid carcinoma at autopsy in La Plata, Argentina. Cancer 1989;64:547-51.
12. Solares CA, Penalozzo MA, Xu M, Orellana E. Occult papillary thyroid carcinoma in postmortem species: prevalence at autopsy. Am J Otolaryngol 2005;26:87-90.
13. Neuhold N, Kaiser H, Kaserner K. Latent carcinoma of the thyroid in Austria: a systematic autopsy study. Endocr Pathol 2001;12:23-31.
14. Piersanti M, Ezzat S, Asa SL. Controversies in papillary microcarcinoma of the thyroid. Endocr Pathol 2003;14: 183-91.
15. Leenhardt L, Heijblum G, Franc B, Fediaevsky LD, Delbot T, Le Guillouzic D, et al. Indications and limits of ultrasonography-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab 1999;84:24-8.
16. Kim EK, Park CS, Chung WY, Oh KK, Kim DI, Lee JT, et al. New sonographic criteria for recommending...
fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol 2002;178:687-91.
17. Wiest PW, Hartshorne MF, Insksip PD, Crooks LA, Vela BS, Telepak RJ, et al. Thyroid palpation versus high-resolution thyroid ultrasonography in the detection of nodules. J Ultrasound Med 1998;17:487-96.
18. Carroll BA. Asymptomatic thyroid nodules: incidental sonographic detection. AJR Am J Roentgenol 1982;138:499-501.
19. Naik KS, Bury RF. Imaging the thyroid. Clin Radiol 1998;53:630-9.
20. Bennedbaek FN, Hegedüs L. Management of the solitary thyroid nodule: results of a North American survey. J Clin Endocrinol Metab 2000;85:2493-8.
21. Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab 2006;91:3411-7.
22. Mitchell J, Parangi S. The thyroid incidentaloma: an increasingly frequent consequence of radiologic imaging. Semin Ultrasound CT MR 2005;26:37-46.
23. Lin JD, Chao TC, Weng HF, Huang HS, Ho YS. Clinical presentations and treatment for 74 occult thyroid carcinoma. Comparison with nonoccult thyroid carcinoma in Taiwan. Am J Clin Oncol 1996;19:504-8.
24. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7.
25. Baloch ZW, LiVolsi VA. Microcarcinoma of the thyroid. Adv Anat Pathol 2006;13:69-75.
26. Ito Y, Urano T, Nakano K, Takamura Y, Miya A, Kobayashi K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003;13:381-7.
27. Lee J, Rhee Y, Lee S, Ahn CW, Cha BS, Kim KR, et al. Frequent, aggressive behaviors of thyroid microcarcinomas in Korean patients. Endocr J 2006;53:627-32.
28. Kasai N, Sakamoto A. New subgrouping of small thyroid carcinomas. Cancer 1987;60:1767-70.
29. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997;126:226-31.
30. Gharib H. Changing concepts in the diagnosis and management of thyroid nodules. Endocrinol Metab Clin North Am 1997;26:777-800.
31. Burguera B, Gharib H. Thyroid incidentalomas. Prevalence, diagnosis, significance, and management. Endocrinol Metab Clin North Am 2000;29:187-203.
32. Miki H, Oshimo K, Inoue H, Kawano M, Tanaka K, Komaki K, et al. Incidence of ultrasonographically-detected thyroid nodules in healthy adults. Tokushima J Exp Med 1993;40:43-6.
33. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002;87:1941-6.
34. Silver RJ, Parangi S. Management of thyroid incidentalomas. Surg Clin North Am 2004;84:907-19.